Optimal effective doses of cabergoline and bromocriptine and valvular leasions in men with prolactinomas

Neuroendocrinology Letters

Volumn 33, Issue 3, 2012, Pages 340-346

  Yarman, Sema ^a   Kurtulmus, Neslihan ^b   Bilge, Ahmet ^c  

^a ISTANBUL UNIVERSITY   (Turkey)

^b Acibadem Maslak Hospital Eye Clinic   (Turkey)

^c Department of Cardiology ^*  (Turkey)

Author keywords

Cumulative dose; Dopamine agonist; Men; Prolactinoma; Valvulopathy

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; HYDROCORTISONE;

ADULT; AGED; ANDROGEN DEFICIENCY; ARTICLE; CLINICAL ARTICLE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; ECHOCARDIOGRAPHY; FOLLOW UP; HEADACHE; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPOGONADISM; HYPOTHYROIDISM; IMPOTENCE; LIBIDO DISORDER; MALE; MEDICAL RECORD REVIEW; MONOTHERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PROLACTINOMA; RETROSPECTIVE STUDY; TREATMENT DURATION; TUMOR GROWTH; VALVULAR HEART DISEASE;

EID: 84862222796     PISSN: 0172780X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Antonini A, Poewe W (2007). Fibrotic heart-valve reactions to dopamine agonist treatment in Parkinson's disease. Lancet Neurol. 6: 826-829. (Pubitemid 47243713)
2. Berezin M, Shimon I, Hadani M (1995). Prolactinoma in 53 men: clinical characteristics and modes of treatment (male prolactinoma). J Endocrinol Invest. 18: 436-441.
3. Biller BM, Molitch ME, Vance ML, Cannistraro KB, Davis KR, Simons JA, et al. (1996). Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline. J Clin Endocrinol Metab. 81: 2338-2343. (Pubitemid 26175965)
4. Bogazzi F, Buralli S, Manetti L, Raffaelli V, Cigni T, Lombardi M, et al. (2008). Treatment with low doses of cabergoline is not associated with increased prevalence of cardiac valve regurgitation in patients with hyperprolactinemia. Int J Clin Pract. 62: 1864-1869.
5. Chattopadhyay A, Bhansali A, Masoodi SR (2005). Long-term efficacy of bromocriptine in macroprolactinomas and giant prolactinomas in men. Pituitary 8: 147-154.
6. Cho EH, Lee SA, Chung JY, Koh EH, Cho YH, Kim JH, et al. (2009). Efficacy and safety of cabergoline as first line treatment for invasive giant prolactinoma. J Korean Med Sci. 24: 874-878.
7. Colao A, di Sarno A, Pivonello R, di Somma C, Lombardi G (2002). Dopamine receptor agonists for treating prolactinomas. Expert Opin Investig Drugs. 11: 787-800. (Pubitemid 34618811)
8. Colao A, Galderisi M, Di Sarno A, Pardo M, Gaccione M, D'Andrea M, et al. (2008). Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline. J Clin Endocrinol Metab. 93: 3777-3784.
9. Colao A, Vitale G, Cappabianca P, Briganti F, Ciccarelli A, De Rosa M, et al. (2004). Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactine levels, tumor mass, recovary of pituitary function, and semen analysis. J Clin Endocrinol Metab. 89: 1704-1711. (Pubitemid 38507923)
10. Corsello SM, Ubertini G, Altomare M, Lovicu RM, Migneco MG, Rota CA, et al. (2003). Giant prolactinomas in men:efficacy of cabergoline treatment. Clin Endocrinol. 58: 662-670. (Pubitemid 36566810)
11. Dekkers OM, Lagro J, Burman P, Jorgensen JO, Romijn JA, Pereira A (2010). Recurrence of hyperprolactinemia after withdrawal of dopamine agonists:Systemic Review and Meta-Analysis. J Clin Endocrinol Metab. 95: 43-51.
12. Delgrange E, Trouillas J, Maiter D, Donckier J, Tourniaire J (1997). Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study. J Clin Endocrinol Metab. 82: 2102-2107. (Pubitemid 27287568)
13. Devin JK, Lakhani VT, Byrd BF 3rd, Blevins LS Jr (2008). Prevalence of valvular heart disease in a cohort of patients taking cabergoline for management of hyperprolactinemia. Endocr Pract. 14: 672-677.
14. Grisoli F, Vincentelli F, Jaquet P, Guibout M, Hassoun J, Farnarier P (1980). Prolactin secreting adenoma in 22 men. Surg Neurol. 13: 241-247. (Pubitemid 10148693)
15. Herring N, Szmigielski C, Becher H, Karavitaki N, Wass JA (2009). Valvular heart disease and the use of cabergoline for the treatment of prolactinoma. Clin Endocrinol (Oxf). 70: 104-108.
16. Hulting AL, Muhr C, Lundberg PO, Werner S (1985). Prolactinomas in men: clinical characteristics and the effect of bromocriptine treatment. Acta Med Scand. 217: 101-109. (Pubitemid 15128929)
17. Kars M, Delgado V, Holman ER, Feelders RA, Smit JW, Romijn JA (2008). Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma. J Clin Endocrinol Metab. 93: 3348-3356.
18. Kharlip J. Salvatori, R, Yenokyan G, Wand G (2009). Recurrence of Hyperprolactinemi after Withdrawal of Long-Term Cabergoline Therapy. J Clin Endocrinol Metab. 94: 2428-2436.
19. Kim JY, Chung EJ, Park SW, Lee WY (2006). Valvular heart disease in Parkinson's disease treated with ergot derivative dopamine agonists. Mov Disord. 21: 1261 -1264.
20. Lancellotti P, Livadariu E, Markov M, Daly AF, Burlacu MC, Betea D, et al. (2008). Cabergoline and the risk of valvular lesions in endocrine disease. Eur J Endocrinol. 159: 1-5. (Pubitemid 351969123)
21. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. (2005). Recommendations for chamber quantification: A report from American Society of Echocardiography's Guidelines and Standard Committee and the Chamber Quantification Writing Group, developed in conjuction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 18: 1440-1463. (Pubitemid 41821197)
22. Minniti G, Jaffrain-Rea ML, Santoro A, Esposito V, Ferrante L, Delfini R, Cantore G. (2002). Giant prolactinomas presenting as skull base tumors. Surg Neurol. 57: 99-103. (Pubitemid 34211332)
23. Nachtigall L, Valassi E, Lo J, McCarty D, Passed J, Biller BM, et al. (2010). Gender effects on cardiac valvular function in hyperprolactinaemic patients receiving cabergoline: a retrospective study. Clin Endocrinol (Oxf). 72: 53-58.
24. Nishioka H, Haraoka J, Akada K (2003). Growth potantiel of prolactinomas in men: is it really different from women? Surg Neurol. 59: 386-390. (Pubitemid 36583605)
25. Pinzone JJ, Katznelson L, Danila DC, Pauler DK, Miller CS, Klibanski A (2000). Primary medical therapy of micro- and macroprolactinomas in men. J Clin Endocrinol Metab. 85: 3053-3057.
26. Roth BL (2007). Drugs and valvular heart disease. N Engl J Med. 356: 6-9.
27. Serratrice J, Disdier P, Habib G, Viallet F, Weiller PJ (2002). Fibrotic valvular heart disease subsequent to bromocriptine treatment. Cardiol Rev. 10: 334-336. (Pubitemid 35266254)
28. Shade R, Andershon F, Suissa S, Haverkamp W, Garbe E (2007). Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med. 356: 29-38. (Pubitemid 46041751)
29. Shimon I, Benbassat C, Hadani M (2007). Effectiveness of long-term cabergoline treatment for giant prolactinoma: study of 12 men. Eur J Endocrinol. 156: 225-231. (Pubitemid 46554517)
30. Shrivastava RK, Arginteanu MS, King WA, Post KD (2002). Giant prolactinomas: clinical management and long-term follow up. J Neurosurg. 97: 299-306. (Pubitemid 34827329)
31. Tan LC, Ng KK, WL Au, Lee RK, Chan YH, Tan NC (2009). Bromocriptine Use and the Risk of Valvular Heart Disease. Mov Disord. 24: 344-349.
32. Valassi E, Klibanski A, Biller BM (2010). Potential cardiac valve effects of dopamine agonists in hyperprolactinemia. J Clin Endocrinol Metab. 95: 1025-1033.
33. Vallette S, Serri K, Rivera J, Santagata P, Delorme S, Garfield N, ef al. (2009). Long-term cabergoline therapy is not associated with valvular heart disease in patients with prolactinomas. Pituitary. 12: 153-157.
34. Vance ML, Thorner MO (1987). Prolactinomas. Endocrinol Metab Clin North Am. 16: 731-753. (Pubitemid 18077312)
35. Verhelst J, Abs R, Maiter D, van den Bruel A, Vandeweghe M, Velkeniers B, et al. (1999). Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J Clin Endocrinol Metab. 84: 2518-2522.
36. Wakil A, Rigby AS, Clark AL, Kallvikbacka-Bennett A, Atkin SL (2008). Low dose of cabergoline for hyperprolactinemia is not associated with clinically significant valvular heart disease. Eur J Endocrinol. 159: R11-14.
37. Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G (2007). Valvular heart disease and the use of dopamine agonists for Parkinsons disease. N Engl J Med. 356: 39-46. (Pubitemid 46041752)